Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Ophthalmology · Scleritis

Understanding Idiopathic Scleritis: Orientation & Overview

At a Glance

Idiopathic scleritis means the sclera, the white outer wall of the eye, is inflamed but no cause has been found yet. It can cause severe pain and redness, needs specialist evaluation, and may require monitoring because another disease can appear later.

If you are reading this, you may have just learned you have idiopathic scleritis. This diagnosis can feel overwhelming, especially because the word “idiopathic” sounds like a specific disease name when it actually describes what doctors haven’t found yet.

Scleritis is a serious inflammatory condition affecting the sclera, the tough, white outer wall of your eye [1]. When your doctor adds the word “idiopathic,” they are using a medical term that means “of unknown cause” [2]. Essentially, it is a diagnosis of exclusion: it means your medical team has looked for common triggers—such as an underlying autoimmune disease (like rheumatoid arthritis), an infection (like shingles or tuberculosis), a reaction to a medication, or a recent eye surgery—and found no evidence that any of them are the cause [2][3][4].

Navigating a Rare Condition

It is common to feel anxious or even isolated after receiving this diagnosis. Scleritis is quite rare. Large-scale studies estimate that only about 1 to 5.5 people out of every 100,000 will develop scleritis in a given year [5][6]. Because it is so uncommon, you might find that primary care doctors or even some general eye specialists (optometrists) may not recognize it immediately, often mistaking it for a more common “red eye” condition [7].

Finding an ophthalmologist who specializes in uveitis (eye inflammation) or ocular immunology can be helpful, as they are specifically trained to manage these rare inflammatory conditions and differentiate them from less severe issues [2].

Scleritis vs. Episcleritis: Why the Difference Matters

One of the most frequent hurdles in getting a correct diagnosis is that scleritis looks very similar to a much milder condition called episcleritis. While they sound alike, they involve different layers of the eye and carry very different risks:

Feature Episcleritis Scleritis
Location Superficial tissue over the sclera [8] Deep (the actual wall of the eye) [1]
Pain Level Usually mild discomfort or “grittiness” [9] Typically severe, boring ache that can wake you up at night [2]
Vessel Color Bright red [1] Deep red, bluish, or purple (violaceous) hue [10]
Risk Generally benign and self-limited, though it can recur [9] Can lead to vision loss or “melting” of the eye wall if untreated [11]
Phenylephrine Test* Redness “blanches” (turns white) with certain eye drops [12] Redness often stays deep red or purple even after drops [13]

*Note: The phenylephrine blanching test is a clinical tool performed by an eye doctor in the office. It is not perfectly definitive on its own, and patients should never attempt to self-test with over-the-counter redness-relief eye drops at home.

Misdiagnosing scleritis as episcleritis is problematic because episcleritis often goes away without aggressive treatment, whereas scleritis requires active medical management to prevent damage to the eye’s structure [11][1].

The Proposed Biology of the “Aching Eye”

To understand why your eye is inflamed, it helps to look at what researchers believe is happening at a microscopic level. In idiopathic scleritis, the condition is often presumed to be immune-mediated. This means your immune system may mistakenly target the sclera, triggering a cascade of events:

  1. Immune Cell Invasion: Specialized white blood cells, particularly T-cells, may migrate into the scleral tissue [14].
  2. Chemical Signaling: These cells can release proteins called cytokines (such as TNF and IL-6) that act like biological “alarm bells,” keeping the inflammation active [15].
  3. Tissue Remodeling: The inflammation may cause the production of enzymes called matrix metalloproteinases (MMPs) [16]. In scleritis, they can begin to break down the collagen that gives the sclera its strength, potentially leading to thinning or “melting” of the eye wall [17][18].
  4. Vascular Changes: The deep blood vessels in the eye wall become engorged and leaky, which contributes to the characteristic deep-red appearance and the intense pressure-like pain often reported by patients [16][19].

While these molecular changes describe the proposed mechanisms, they are not usually measured to diagnose or monitor an individual patient.

Why “Idiopathic” Can Change Over Time

It is important to know that an idiopathic diagnosis isn’t always “final.” In some cases, scleritis is the very first sign of an underlying disease that hasn’t fully shown up in the rest of your body yet [20]. Research shows that a portion of people initially diagnosed with idiopathic scleritis may develop a recognizable systemic condition (like vasculitis) months or even years later [21]. For this reason, your care will likely involve ongoing monitoring and perhaps repeat blood work to ensure that your “unknown cause” hasn’t become a “known cause” that requires a different approach [2][21].

Common questions in this guide

What does “idiopathic” mean in idiopathic scleritis?
It means doctors found inflammation of the sclera but did not identify an underlying cause after evaluating for conditions such as autoimmune disease, infection, medication reactions, or recent eye surgery. It does not always mean the cause will remain unknown, so follow-up may be important.
How can doctors tell scleritis from episcleritis?
Scleritis affects the deeper wall of the eye and usually causes severe deep pain, while episcleritis affects tissue on the surface and is often milder. An eye doctor also considers the shade and depth of the blood vessels and whether redness fades with a clinical eye-drop test; do not try this test at home.
Why does idiopathic scleritis cause a painful red eye?
Inflammation makes the deeper blood vessels in the sclera swollen and leaky, producing a deep red or purple appearance and pressure-like pain. The inflammation can also weaken the collagen that supports the eye wall, which is why untreated scleritis can threaten the eye.
Can idiopathic scleritis be the first sign of another illness?
Yes. In some people, scleritis appears before an autoimmune or blood-vessel disease becomes recognizable elsewhere in the body. Follow-up visits and sometimes repeat blood tests help clinicians check whether a specific cause emerges.
Which specialist should I see for idiopathic scleritis?
An ophthalmologist with expertise in uveitis or ocular immunology can evaluate this uncommon form of eye inflammation and distinguish it from less serious red-eye conditions. Your specialist can also decide what monitoring is appropriate.
What symptoms outside the eye should I tell my doctor about?
Tell your doctor about new joint pain, skin rashes, or a persistent cough, because these symptoms may help identify an underlying condition. Sharing changes in your vision and the timing and character of your eye pain is also important.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is my inflammation limited to the surface (episclera) or does it involve the deeper wall of the eye (sclera)?
  2. 2.Which tests were used to rule out systemic autoimmune diseases like rheumatoid arthritis or vasculitis?
  3. 3.What clinical signs—such as vessel color, vessel depth, or response to eye drops—led to the diagnosis of scleritis?
  4. 4.Is my scleritis classified as diffuse, nodular, or necrotizing, and how does that affect my long-term outlook?
  5. 5.If my symptoms don't improve with the initial plan, what is the next step for re-evaluating the cause?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    [Diagnostic and Therapeutic Management of Episcleritis and Scleritis].

    Turgut F, Dingerkus V, Tappeiner C, Becker M

    Klinische Monatsblatter fur Augenheilkunde 2023; (240(5)):725-738 doi:10.1055/a-2022-0689.

    PMID: 36827997
  2. 2

    Current Approach for the Diagnosis and Management of Noninfective Scleritis.

    Dutta Majumder P, Agrawal R, McCluskey P, Biswas J

    Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) 2020; (10(2)):212-223 doi:10.1097/APO.0000000000000341.

    PMID: 33290287
  3. 3

    Infectious scleritis: a review of etiologies, clinical features, and management strategies.

    Sharma S, Sheth JU, Murthy SI

    Frontiers in ophthalmology 2025; (5()):1493831 doi:10.3389/fopht.2025.1493831.

    PMID: 39990248
  4. 4

    Systemic Disease Associations in a Cohort of Hispanic Patients with Scleritis.

    Arruza C, Requejo Figueroa GA, Colón J, et al.

    Journal of clinical medicine 2023; (12(5)) doi:10.3390/jcm12051969.

    PMID: 36902755
  5. 5

    The Global Epidemiology of Scleritis: A Systematic Review and Meta-analysis.

    Cifuentes-González C, Mejía-Salgado G, Rojas-Carabali W, et al.

    American journal of ophthalmology 2025; (273()):13-32 doi:10.1016/j.ajo.2025.01.019.

    PMID: 39892801
  6. 6

    Epidemiology and Clinical Characteristics of Episcleritis and Scleritis in Olmsted County, Minnesota.

    Xu TT, Reynolds MM, Hodge DO, Smith WM

    American journal of ophthalmology 2020; (217()):317-324 doi:10.1016/j.ajo.2020.04.043.

    PMID: 32437669
  7. 7

    Monocular posterior scleritis presenting as acute conjunctivitis: A case report.

    Li YZ, Qin XH, Lu JM, Wang YP

    World journal of clinical cases 2020; (8(20)):5030-5035 doi:10.12998/wjcc.v8.i20.5030.

    PMID: 33195678
  8. 8

    Etanercept-associated episcleritis: a pediatric case report of a paradoxical adverse reaction and review of the literature.

    Küçükali B, Gezgin Yıldırım D, Esmeray Şenol P, et al.

    Clinical rheumatology 2024; (43(2)):799-808 doi:10.1007/s10067-023-06793-4.

    PMID: 37845415
  9. 9

    [Diagnosis and treatment of episcleritis and scleritis].

    Tappeiner C, Walscheid K, Heiligenhaus A

    Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 2016; (113(9)):797-810 doi:10.1007/s00347-016-0344-3.

    PMID: 27550224
  10. 10

    Insights into scleral violaceous hue in anterior scleritis: anterior segment optical coherence tomography evaluation.

    Sutra P, Pothikamjorn T, Lopez S, et al.

    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2025; (263(7)):1997-2004 doi:10.1007/s00417-025-06788-8.

    PMID: 40095049
  11. 11

    Epidemiology of episcleritis and scleritis in urban Australia.

    Thong LP, Rogers SL, Hart CT, et al.

    Clinical & experimental ophthalmology 2020; (48(6)):757-766 doi:10.1111/ceo.13761.

    PMID: 32279425
  12. 12

    Nodular anterior scleritis associated with Berger's disease.

    Constancio EG, Alves DLS, Mello LGM, et al.

    Arquivos brasileiros de oftalmologia 2021; (84(1)):74-77 doi:10.5935/0004-2749.20210011.

    PMID: 33470345
  13. 13

    Atypical Cogan's Syndrome Presenting as Anterior Scleritis: Case Report.

    Mendes J, Mendes F, Valente Fortunato D, et al.

    Case reports in ophthalmology 2026; (17(1)):371-379 doi:10.1159/000551227.

    PMID: 42039758
  14. 14

    Rituximab in the Treatment of Refractory Noninfectious Scleritis.

    Cao JH, Oray M, Cocho L, Foster CS

    American journal of ophthalmology 2016; (164()):22-8.

    PMID: 26766304
  15. 15

    Identifying TNF and IL6 as potential hub genes and targeted drugs associated with scleritis: A bio-informative report.

    Yan F, Liu Y, Zhang T, Shen Y

    Frontiers in immunology 2023; (14()):1098140 doi:10.3389/fimmu.2023.1098140.

    PMID: 37063831
  16. 16

    Potential Biomarkers for Noninfectious Scleritis Identified by Serum and Tear Fluid Proteomics.

    Vergouwen DPC, Kolijn PM, de Hoog J, et al.

    Ophthalmology science 2024; (4(1)):100407 doi:10.1016/j.xops.2023.100407.

    PMID: 38054106
  17. 17

    Scleraxis expressing scleral cells respond to inflammatory stimulation.

    Atta G, Schroedl F, Kaser-Eichberger A, et al.

    Histochemistry and cell biology 2021; (156(2)):123-132 doi:10.1007/s00418-021-01985-y.

    PMID: 33966129
  18. 18

    Current insights in the pathogenesis of scleritis.

    Vergouwen DPC, Rothova A, Berge JCT, et al.

    Experimental eye research 2020; (197()):108078 doi:10.1016/j.exer.2020.108078.

    PMID: 32504648
  19. 19

    Scleral Proteome in Noninfectious Scleritis Unravels Upregulation of Filaggrin-2 and Signs of Neovascularization.

    Vergouwen DPC, Ten Berge JC, Guzel C, et al.

    Investigative ophthalmology & visual science 2023; (64(3)):27 doi:10.1167/iovs.64.3.27.

    PMID: 36930145
  20. 20

    ANCA-associated scleritis: impact of ANCA on presentation, response to therapy and outcome.

    Perray L, Nguyen Y, Clavel Refregiers G, et al.

    Rheumatology (Oxford, England) 2024; (63(2)):329-337 doi:10.1093/rheumatology/kead252.

    PMID: 37233203
  21. 21

    Scleritis and Development of Immune-Mediated Disease: A Retrospective Chart Review.

    Morrison T, Gottman M, Do T, et al.

    The Journal of rheumatology 2024; (51(8)):825-830 doi:10.3899/jrheum.2023-0788.

    PMID: 38302174

This page is for informational purposes only and does not constitute medical advice. An ophthalmologist, especially one who treats uveitis or ocular inflammation, should interpret your symptoms and determine the right evaluation and follow-up for you.

Get notified when new evidence is published on Idiopathic scleritis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.